{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:43:12Z","timestamp":1791499392435,"version":"4.3.4"},"reference-count":176,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006387","name":"Fondation Leenaards","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014601","name":"Neos Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.annonc.2020.03.285","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T07:08:32Z","timestamp":1584428912000},"page":"724-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"title":["Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy"],"prefix":"10.1016","volume":"31","author":[{"given":"J.","family":"Haanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Puzanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.03.285_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"6","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib2","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options","volume":"2","author":"Khan","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib7","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.annonc.2020.03.285_bib8","first-page":"169","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.annonc.2020.03.285_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.annonc.2020.03.285_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00262-014-1607-y","article-title":"Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease","volume":"63","author":"Pedersen","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2020.03.285_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","article-title":"Ipilimumab in patients with melanoma and autoimmune disease","volume":"2","author":"Kyi","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0484-x","article-title":"Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-alpha4beta7 and anti-PD1 antibodies","volume":"7","author":"Frohne","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-016-0309-7","article-title":"Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report","volume":"9","author":"Uemura","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib20","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib21","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1002\/cam4.2397","article-title":"Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control","volume":"8","author":"Hughes","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib22","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib23","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib24","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early Use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib25","doi-asserted-by":"crossref","first-page":"e0195945","DOI":"10.1371\/journal.pone.0195945","article-title":"Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab","volume":"13","author":"Dumenil","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2020.03.285_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","article-title":"Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient","volume":"67","author":"Herz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.ackd.2016.08.002","article-title":"The Bad and the good news on cancer immunotherapy: implications for organ transplant recipients","volume":"23","author":"Maggiore","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib29","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","article-title":"Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient","volume":"152","author":"De Toni","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.annonc.2020.03.285_bib30","doi-asserted-by":"crossref","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuca","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2020.03.285_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib32","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2020.03.285_bib33","first-page":"JCO1901674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib34","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2020.03.285_bib36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in\u00a0vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.annonc.2020.03.285_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2017.02.002","article-title":"Selective expansion of human regulatory T cells in nasal polyps, and not adjacent tissue microenvironments, in individual patients exposed to steroids","volume":"179","author":"Edward","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.celrep.2014.04.041","article-title":"How steroids steer T cells","volume":"7","author":"Libert","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.annonc.2020.03.285_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/cells2020202","article-title":"Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword","volume":"2","author":"Gruver-Yates","year":"2013","journal-title":"Cells"},{"key":"10.1016\/j.annonc.2020.03.285_bib40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.03.285_bib41","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"suppl_11","key":"10.1016\/j.annonc.2020.03.285_bib43","doi-asserted-by":"crossref","first-page":"xi16","DOI":"10.1093\/annonc\/mdz449","article-title":"Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated","volume":"30","author":"De Giglio","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib44","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.285_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2018.36.5_suppl.106","article-title":"Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): a Cytokine Working Group study","volume":"36","author":"Appleman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coph.2019.05.007","article-title":"State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis","volume":"46","author":"Gisondi","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.annonc.2020.03.285_bib47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaad.2017.06.043","article-title":"Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation","volume":"78","author":"Whitlock","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib48","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-018-0481-0","article-title":"A\u00a0severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib51","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.285_bib52","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.annonc.2020.03.285_bib53","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/cas.13330","article-title":"Lack of interleukin-6 in the tumor\u00a0microenvironment augments type-1 immunity and increases the\u00a0efficacy of cancer immunotherapy","volume":"108","author":"Ohno","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.annonc.2020.03.285_bib54","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.annonc.2020.03.285_bib55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.immuni.2013.12.006","article-title":"Th17 cells at the crossroads of autoimmunity, inflammation, and atherosclerosis","volume":"40","author":"van Bruggen","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2020.03.285_bib56","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib57","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ni.1613","article-title":"A\u00a0critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses","volume":"9","author":"Volpe","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib58","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.annonc.2020.03.285_bib60","first-page":"3833","article-title":"TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice","volume":"117","author":"Calzascia","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.annonc.2020.03.285_bib61","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.03.285_bib62","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2020.03.285_bib63","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/0008-5472.CAN-14-2524","article-title":"Blocking tumor necrosis factor alpha enhances CD8 T-cell-dependent immunity in experimental melanoma","volume":"75","author":"Bertrand","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.285_bib64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib65","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","article-title":"The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis","volume":"96","author":"Munger","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2020.03.285_bib67","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.annonc.2020.03.285_bib68","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.annonc.2020.03.285_bib69","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2020.03.285_bib70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib73","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib74","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.annonc.2020.03.285_bib76","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib77","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib78","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"Diaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.annonc.2020.03.285_bib79","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.annonc.2020.03.285_bib80","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib81","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/0961203315578764","article-title":"Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus","volume":"24","author":"Olfat","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.annonc.2020.03.285_bib82","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib83","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2020.03.285_bib84","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfp002","article-title":"Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study","volume":"24","author":"Boletis","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.annonc.2020.03.285_bib85","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.annonc.2020.03.285_bib86","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41467-017-00452-4","article-title":"Tumor-associated B-cells induce tumor heterogeneity and therapy resistance","volume":"8","author":"Somasundaram","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2020.03.285_bib87","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A\u00a0tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.285_bib88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.437","article-title":"Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells","volume":"3","author":"Schlaak","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2020.03.285_bib89","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","article-title":"B\u00a0cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors","volume":"7","author":"Damsky","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib90","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-018-0429-4","article-title":"A\u00a0severe case of neuro-Sjogren's syndrome induced by pembrolizumab","volume":"6","author":"Ghosn","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib91","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/annonc\/mdx252","article-title":"Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient","volume":"28","author":"Ito","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib93","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2018.07.125","article-title":"Rituximab in the treatment of pembrolizumab-induced myasthenia gravis","volume":"102","author":"Crusz","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib94","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib95","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib96","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2863","article-title":"Tocilizumab","volume":"8","author":"Scheinecker","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.annonc.2020.03.285_bib97","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib98","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib99","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091433","article-title":"Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type","volume":"17","author":"Fabre","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annonc.2020.03.285_bib101","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib102","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib103","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib105","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib106","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib107","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib108","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib109","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib111","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib112","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib113","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: A review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.annonc.2020.03.285_bib114","doi-asserted-by":"crossref","first-page":"e000162","DOI":"10.1136\/rmdopen-2015-000162","article-title":"Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases","volume":"1","author":"Izumi","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.annonc.2020.03.285_bib115","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib116","doi-asserted-by":"crossref","first-page":"rky001","DOI":"10.1093\/rap\/rky001","article-title":"Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis","volume":"2","author":"Oke","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.annonc.2020.03.285_bib117","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib118","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib119","first-page":"1682","article-title":"Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease","volume":"13","author":"Hallowell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.annonc.2020.03.285_bib120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.annonc.2020.03.285_bib121","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","article-title":"Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies","volume":"81","author":"Bernard-Tessier","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib122","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5578\/tt.66667","article-title":"Immuno-checkpoint inhibitor-associated hyper-eosinophilia and tumor shrinkage","volume":"66","author":"Osawa","year":"2018","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.annonc.2020.03.285_bib123","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2005.02.006","article-title":"Anti-IL-5 and hypereosinophilic syndromes","volume":"115","author":"Sutton","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib126","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib127","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib129","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib130","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annonc.2020.03.285_bib131","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.annonc.2020.03.285_bib132","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib133","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib134","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib135","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib137","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.annonc.2020.03.285_bib138","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib139","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib140","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib141","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annonc.2020.03.285_bib142","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib143","doi-asserted-by":"crossref","first-page":"e000260","DOI":"10.1136\/rmdopen-2016-000260","article-title":"Treatment of systemic sclerosis: is there any hope for the future?","volume":"2","author":"Allanore","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.annonc.2020.03.285_bib144","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib145","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib146","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib147","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A\u00a0multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib148","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib149","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A\u00a0randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annonc.2020.03.285_bib150","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib151","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annonc.2020.03.285_bib152","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annonc.2020.03.285_bib153","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.03.285_bib154","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2020.03.285_bib155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib156","unstructured":"Shirali AC. Minimizing the impact of imAEs and maximizing efficacy: renal toxicities. Medscape 2019."},{"key":"10.1016\/j.annonc.2020.03.285_bib157","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib158","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib160","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib161","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1093\/annonc\/mdx409","article-title":"Tumor regression and preservation of graft\u00a0function after combination with anti-PD-1 immunotherapy without immunosuppressant titration","volume":"28","author":"Wu","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib162","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.285_bib163","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1111\/ajt.15071","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.annonc.2020.03.285_bib164","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2020.03.285_bib165","first-page":"277","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.annonc.2020.03.285_bib166","doi-asserted-by":"crossref","first-page":"MMT10","DOI":"10.2217\/mmt-2018-0004","article-title":"Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations","volume":"5","author":"Grant","year":"2018","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.annonc.2020.03.285_bib167","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra0902927","article-title":"Rejection of the kidney allograft","volume":"363","author":"Nankivell","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib168","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2020.03.285_bib169","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","article-title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","volume":"3","author":"Morales","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.03.285_bib170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.285_bib171","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2004.09.009","article-title":"Rapamycin: an anti-cancer immunosuppressant?","volume":"56","author":"Law","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.annonc.2020.03.285_bib172","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2005-07-3032","article-title":"Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells","volume":"107","author":"Coenen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2020.03.285_bib173","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"issue":"Suppl 3","key":"10.1016\/j.annonc.2020.03.285_bib174","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.annonc.2020.03.285_bib175","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/ket462","article-title":"Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study","volume":"53","author":"Moroni","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annonc.2020.03.285_bib176","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.annonc.2020.03.285_bib177","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/annonc\/mdw056","article-title":"The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma","volume":"27","author":"Lee","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342036364X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342036364X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:56:56Z","timestamp":1760335016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342036364X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":176,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S092375342036364X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.285","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}